BRCA2 germline pathogenic confers ~2-3× elevated cutaneous melanoma risk and uveal-melano...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA2-GERMLINE-MELANOMA |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MELANOMA |
| Sources | SRC-CIVIC SRC-ESMO-MELANOMA-2024 SRC-NCCN-MELANOMA-2025 |
Actionability Facts
| Biomarker | BIO-BRCA1-BRCA2-GERMLINE |
|---|---|
| Variant | BRCA2 germline pathogenic |
| Disease | DIS-MELANOMA |
| ESCAT tier | IIIA |
| Recommended combinations | standard melanoma therapy by stage/biomarker (ICI, BRAFi+MEKi if BRAF V600), consider PARPi in clinical trial only |
| Evidence summary | BRCA2 germline pathogenic confers ~2-3× elevated cutaneous melanoma risk and uveal-melanoma association; no melanoma-specific PARPi indication exists. Standard melanoma therapy (BRAF/MEKi or ICI) per usual algorithm. PARPi only in clinical-trial context. ESCAT IIIA / OncoKB Level 3B. |
Notes
Germline finding triggers cascade testing — relatives face breast, ovarian, prostate, pancreatic risk regardless of melanoma. Enhanced dermatologic surveillance recommended.
Used By
No reverse references found in the YAML corpus.